Shushan Hovsepyan: Does the choice of chemotherapy regimen make a difference in relapse/progressive high-risk neuroblastoma?
Shushan Hovsepyan, Pediatric Oncologist and Clinical Research Coordinator at the Yeolyan Hematology and Oncology Center, shared the following post on LinkedIn:
“Does the choice of chemotherapy regimen make a difference in relapse/progressive high-risk neuroblastoma?
Here’s what we learned from France’s real-world data on chemo-immunotherapy:
– Thirty-nine patients with relapsed/progressive high-risk neuroblastoma receiving chemo-immuno.
– Similar overall response rates (42% with dinutuximab beta + TopoCyclo and 40% with dinutuximab beta + TOTEM/TEMIRI) were observed.
– Generally safe profile, with mild to moderate adverse effects.
– The median follow-up time for progression-free survival (PFS) and overall survival (OS) was 10 months, 9-month PFS and OS rates were 32% and 53%, respectively.
These findings underscore the significance of chemo-immunotherapy in treating neuroblastoma, irrespective of the specific chemotherapy regimen.”
Read further.
Source: Shushan Hovsepyan/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023